Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Cerilliant
McKinsey
Cipla
Fuji
Deloitte
Daiichi Sankyo
US Army
Teva
Chinese Patent Office

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,514,531

« Back to Dashboard

Which drugs does patent 6,514,531 protect, and when does it expire?

Patent 6,514,531 protects AMBIEN CR and is included in one NDA.

Protection for AMBIEN CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty patent family members in twenty-seven countries.
Summary for Patent: 6,514,531
Title: Controlled-release dosage forms comprising zolpidem or a salt thereof
Abstract:The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.
Inventor(s): Alaux; Gerard (Beynes, FR), Lewis; Gareth (Dourdan, FR), Andre; Frederic (Antony, FR)
Assignee: Sanofi-Synthelabo (Paris, FR)
Application Number:09/857,154
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device; Composition;

Drugs Protected by US Patent 6,514,531

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-002 Sep 2, 2005 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-001 Sep 2, 2005 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,514,531

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98403037Dec 04, 1998
PCT Information
PCT FiledDecember 01, 1999PCT Application Number:PCT/EP99/10454
PCT Publication Date:June 15, 2000PCT Publication Number: WO00/33835

International Patents Family Members for US Patent 6,514,531

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1135125 ➤ Subscribe
Portugal 1135125 ➤ Subscribe
Poland 198396 ➤ Subscribe
Poland 348782 ➤ Subscribe
New Zealand 511750 ➤ Subscribe
Norway 20012668 ➤ Subscribe
South Korea 20100130647 ➤ Subscribe
Japan 2010070572 ➤ Subscribe
Japan 4574857 ➤ Subscribe
Japan 2002531499 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
AstraZeneca
Medtronic
Deloitte
Merck
Colorcon
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot